VA Expands Psilocybin Research: Policy and Access Implications for U.S. Veterans

VA Expands Psilocybin Research for Veterans

The U.S. Department of Veterans Affairs (VA) is formally expanding its research into psilocybin, the psychoactive compound found in certain mushrooms, for mental health conditions affecting veterans. This marks a significant shift in federal engagement with psychedelic research, as the VA historically maintained a cautious stance on Schedule I substances. The expansion, announced in September 2026, includes new clinical trial sites and partnerships with academic medical centers, aiming to address high rates of treatment-resistant depression and post-traumatic stress disorder (PTSD) among veterans.

Mechanisms and Federal Context: Why the VA Is Investing Now

The VA’s decision to scale up psilocybin research is driven by persistent unmet mental health needs among veterans and emerging evidence from early-phase trials. Several Phase 2 studies, such as NCT04670081 and NCT03715127, have shown promising safety and efficacy signals for psilocybin-assisted therapy in depression and PTSD. The VA is leveraging its national research infrastructure, including the VA Cooperative Studies Program, to coordinate multi-site trials and ensure rigorous oversight. This expansion aligns with the Biden administration’s broader push for mental health innovation and follows the FDA’s 2024 designation of psilocybin as a Breakthrough Therapy for treatment-resistant depression. Notably, the VA’s move may also be influenced by legislative momentum, such as the 2025 Veterans Psychedelic Therapy Access Act (S. 4192), which directed federal agencies to investigate alternative therapies for veterans.

Policy, Access, and Research Implications

The VA’s expanded research program could set national precedents for the integration of psychedelics into public health systems. By conducting large-scale, federally funded trials, the VA can generate high-quality data on safety, efficacy, and implementation in real-world veteran populations. This may inform future policy decisions, including potential rescheduling of psilocybin or the development of VA-specific clinical guidelines. However, the expansion also raises complex questions about eligibility and access. Veterans with security clearances or on certain medications may be excluded from trials, and the VA has not yet clarified how it will address long-term support for participants after studies conclude. A less-discussed but critical issue is the potential for disparities in access, as rural and underserved veterans may face logistical barriers to participating in research located at major VA medical centers.

Risks, Uncertainties, and Veteran Concerns

While psilocybin shows promise, significant risks and unknowns remain. Adverse events in clinical trials have included transient anxiety, confusion, and rare cases of psychological distress requiring additional care. The long-term effects of repeated psilocybin administration in veterans—many of whom have complex trauma histories—are not well understood. Veterans have raised concerns about confidentiality, especially for those with active security clearances, and about the continuity of care after research participation. The VA’s current protocols for post-trial support and integration of psychedelic experiences into ongoing mental health care are still under development. A concrete example of a failure mode, not widely discussed in public discourse, is the risk that veterans who do not respond to psilocybin in research settings may become disillusioned with the VA or disengage from other evidence-based treatments, underscoring the need for careful participant screening and follow-up.

Looking Ahead: Next Steps and Watch Points

The VA’s expansion of psilocybin research represents a pivotal moment for federal mental health policy and psychedelic science. Key watch points in the coming year include the publication of interim results from ongoing VA trials, updates to eligibility criteria, and the development of protocols for long-term participant support. The outcome of these efforts will likely influence broader federal policy, including potential rescheduling of psilocybin and the integration of psychedelic therapies into other federal health systems. For now, the VA’s approach is cautious but pragmatic, balancing the promise of innovation with the need to protect vulnerable veteran populations. Stakeholders should monitor not just the clinical outcomes, but also the operational lessons learned as the VA navigates this new therapeutic frontier.

By Dr. Alex J. Thompson, PhD (Neuroscience, Policy Editor). How we research: Reviewed by Dr. Alex J. Thompson on 2026-09-23. Sources: VA Research Service, NCT04670081, S. 4192, FDA Breakthrough Therapy Designation.